Filing Flows › Aytu Biopharma (AYTU) › Q1 FY26
Aytu Biopharma (AYTU) Q1 FY26 earnings results (first quarter fiscal 2026)
10-Q filed Nov 13, 2025
Aytu Biopharma (AYTU) reported revenue of $13.9M for the first quarter fiscal 2026 (Q1 FY26), -16% from a year earlier and -8% from the quarter before. Operating margin was -10.8%, net earnings $2.0M (14.1% of revenue).
Aytu Biopharma, Q1 FY26: revenue $13.9M (-16% year over year), operating margin -10.8%, net earnings $2.0M, operating cash flow −$618K. The chart follows the revenue to costs, profit and cash.
| Q1 FY26 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $13.9M | -8% | -16% |
| Operating profit | −$1.5M | — | — |
| Net earnings | $2.0M | — | — |
| Operating cash flow | −$618K | -122% | — |
What changed
Revenue was $13.9M in Q1 FY26, down 16% year over year and down 8% from the previous quarter.
Gross margin was 66.1%, down 6.2 points from a year earlier. Operating costs exceeded revenue by $1.5M, an operating margin of -10.8%. Operating expenses fell 17% while revenue fell 16%. Net earnings were $2.0M, up 33% year over year. The effective tax rate was 0.0%. Non-operating items added $3.5M, 177% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$618K. Non-cash charges added back $803K of depreciation and amortization and $114K of share-based compensation. Working capital and other items used $3.5M.
Questions
What was Aytu Biopharma's revenue in the first quarter fiscal 2026?
Aytu Biopharma (AYTU) reported revenue of $13.9M for the first quarter fiscal 2026 (Q1 FY26), -16% from a year earlier and -8% from the quarter before.
Was Aytu Biopharma profitable in the first quarter fiscal 2026?
Operating loss was $1.5M (-10.8% of revenue) and net earnings $2.0M.
Source: Aytu Biopharma 10-Q on SEC EDGAR.